A R T I C L E S
minal two-thirds of PrP, changes in tyrosine solvent access are probably indicative of conformational changes in this 'structured domain' [14] [15] [16] , which also contributes to the infectious, protease-resistant fragment of PrP Sc (refs. 4-6) .
Tyr-Tyr-Arg antibodies selectively recognize PrP Sc
The majority of tyrosine residues in the structured domain of PrP appear in pairs conserved across mouse, hamster, sheep, bovine and human PrP (Fig. 1c) . Two tyrosine pairs, located in α-helix 1 and β-strand 2, are found in conjunction with a C-terminal arginine (human sequence residues 149-151 and 162-164, respectively), whereas a tyrosine pair at the C terminus of helix 3 (residues 225-227) is flanked by a C-terminal aspartate in mouse and hamster or a glutamine in sheep, bovine and human PrP. We reasoned that the increased solvent exposure of tyrosyl side chains in β-sheet-rich recombinant PrP might involve at least one such bi-tyrosine motif. Furthermore, if recombinant β-sheet-rich models some structural features of PrP Sc (refs. 10-12) , antibody access to one or several TyrTyr-X motifs may provide a PrP Sc -selective conformational epitope.
To test this hypothesis, rabbits were immunized with Tyr-Tyr-Arg-NH 2 peptides coupled through an N-terminal cysteine residue to keyhole limpet hemocyanin (KLH). Purified rabbit IgG fractions were conjugated to magnetic beads and used in immunoprecipitation experiments with normal and prion-infected brain homogenates (see Supplementary Methods online). This bead-conjugated antibody (designated C2) specifically immunoprecipitated PrP Sc from ME7 scrapie-infected mouse brain homogenates (Fig. 2a , lanes 11 and 12; Table 1 ) but not PrP C from uninfected brains (Fig.  2a, lanes 9 and 10) . Additionally, the C2 polyclonal antibody immunoprecipitated the protease-resistant core of PrP Sc (PrP (27) (28) (29) (30) ) from protease K-treated mouse scrapie brain homogenates (Fig. 2a, lane 12) , indicating that its reactivity was not directed against the protease-sensitive domain of PrP Sc (residues 23 to ∼90) or against a protease-sensitive coprecipitated protein. As controls, magnetic beads coupled with monoclonal antibody 6H4, which recognizes an epitope present on both PrP C and PrP Sc (ref. 7) , immunoprecipitated PrP from both normal and prion-infected brain (Fig. 2a, lanes 1-4) , whereas beads coupled to BSA (Fig. 2a,  lanes 5-8) or preimmune sera ( 
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Tyr-Tyr-Arg antibodies recognize PrP Sc from prion-infected brains of multiple species. Reactivity (graded -, + or ++) was compiled from at least three brain immunoprecipitations. ND, not determined; pre, pre-immune sera. We used mouse prion strains ME7 and 139A, hamster strain 263K and human prion disease strains variant CJD, classical sporadic CJD and GSS. a CJD and GSS only. b Variant CJD only.
We next generated Tyr-Tyr-Arg monoclonal antibodies by immunizing BALB/c mice with KLH conjugated to the peptide CYYRRYYRYY (this peptide sequence was chosen because one PrP bi-tyrosine motif is flanked by arginine at both N and C termini). Sixty monoclonal antibodies were selected by ELISA screening against the Tyr-Tyr-Arg antigen coupled to a backbone comprising branched lysines (four-branch multiple antigen peptide; 4-MAP). Ten monoclonal antibodies binding 4-MAP-Tyr-Tyr-Arg, but not control 4-MAP-Ala-Ala-Ala, were tested for PrP Sc -specific recognition by immunoprecipitation as described above. All ten monoclonal antibodies displayed PrP Sc -specific immunoprecipitation from scrapie-infected ME7 and 139A mouse brain or 263K infected hamster brain, and from naturally prion-infected sheep and cattle ( Table 1) . Some monoclonal antibodies preferentially recognized PrP Sc from a subset of these species, suggesting that the monoclonal antibodies did not recognize identical epitopes, a findingsupported by peptide competition experiments (see below). Immunoprecipitation studies performed with two monoclonal antibodies (1A12 and 17D10) are shown (Fig. 2b) . Magnetic beads coupled to the positive control monoclonal antibody 6H4 immunoprecipitated PrP from both normal and prion-infected tissues, whereas beads coupled to three isotype-control monoclonal antibodies immunoprecipitated neither PrP isoform ( Fig. 2b and Table  1 ). In addition, monoclonal antibodies to Tyr-Tyr-Arg selectively immunoprecipitated PrP Sc from prion-infected human brain homogenates (two classical sporadic CJD, one GSS, and three variant CJD) but did not immunoprecipitate PrP from 12 brains of other neurological diseases (Fig. 2c,d , Table 1 and data not shown). Direct efficiency comparison of the sensitivity of protease K digestion and Tyr-Tyr-Arg monoclonal antibody immunoprecipitation showed comparable signal in most species and brain regions (Fig. 2a,d ) but revealed that selected prion disease brains contain immunoprecipitatable PrP, which is poorly resistant to protease K (Fig. 2d and data not shown).
Although PrP Sc -specific polyclonal IgG antibodies to Tyr-Tyr-Arg have been successfully raised in rabbits (Fig. 2a) and goats (data not shown), all mouse monoclonal antibodies to Tyr-Tyr-Arg produced to date have been IgMs, even at the screening stage. In order to exclude the possibility that PrP Sc recognition is a low-affinity interaction dependent on the high avidity conferred by ten IgM antigen-binding sites, we constructed and expressed chimeric IgG monoclonal anti-NATURE MEDICINE VOLUME 9 | NUMBER 7 | JULY 2003 895 bodies from recombinant light-and heavy-chain variable regions of five different Tyr-Tyr-Arg monoclonal antibodies in a dog IgG framework 17 . All five recombinant bivalent IgG antibodies retained selective immunoprecipitation activity against PrP Sc ( Fig. 2e and Table 1 ), consistent with a relatively high-affinity recognition of PrP Sc by the native IgM monoclonal antibodies. Tyr repeats have been reported to define a dominant B-cell epitope 18 , suggesting that the highly skewed IgM monoclonal antibody frequency we observed may be the result of a specific mouse immune response to Tyr-Tyr-Arg antigens.
The PrP Sc Tyr-Tyr-Arg epitope is saturable and specific We carried out antibody competition experiments to test the immunological authenticity of the PrP Sc -selective Tyr-Tyr-Arg epitope (Fig. 3a) . Scrapie-infected hamster brain homogenates were incubated overnight with soluble Tyr-Tyr-Arg monoclonal antibodies 1A12 and 17D10, or the nondistinguishing PrP antibody 6H4, or the control antibody 4E4. These homogenates were then subjected to immunoprecipitation with the same series of antibodies covalently coupled to magnetic beads. (Fig. 3b) , showing that bead quantity is proportional to PrP Sc and PrP (27) (28) (29) (30) content of immunoprecipitates and supernatants. These data are consistent with specific and saturable immune recognition of a discrete PrP Sc epitope by antibodies to Tyr-Tyr-Arg.
To further characterize the Tyr-Tyr-Arg epitope, the fine specificities of 1A12 and 17D10 were determined in a peptide competition ELISA system (Fig. 3c) . As expected, the two Tyr-Tyr-Arg monoclonal antibodies bound to plate-immobilized 4-MAP-Tyr-Tyr-Arg, but the isotype-control monoclonal antibody 4E4 and the isoformnonspecific monoclonal antibody 6H4 did not (data not shown). Plate binding of 1A12 and 17D10 was efficiently inhibited by soluble 4-MAP-Tyr-Tyr-Arg, but not by 4-MAP-Ala-Ala-Ala. Tyr-Tyr-Ala conjugate did not compete for binding of 1A12 or 17D10, whereas Tyr-Ala-Arg conjugate partially competed for the binding of 17D10, but not 1A12. These data suggest that 1A12 and 17D10 possess overlapping, but not identical, specificities in which all three amino-acid side chains participate in epitope recognition, although access to the terminal tyrosine and arginine residues may be more important than the central tyrosine.
Our data indicate that the PrP Sc -specific Tyr-Tyr-Arg epitope must be cryptic in PrP C , but exposed to antibody binding in PrP Sc . Efforts to immunoprecipitate β-sheet-rich recombinant mouse PrP treated at low pH (Fig. 1a,b) revealed that this preparation bound nonspecifically to all tested antibodies, including isotype-control monoclonal antibodies (data not shown). However, PrP C in normal human and mouse brain homogenates treated under identical conditions 19 acquires the Tyr-Tyr-Arg epitope (Fig. 3d and data not  shown) , suggesting that the tripeptide epitope is exposed when PrP is partially denatured in the context of native post-translational modifications (including two N-linked glycans and a glycosyl-phosphatidylinositol anchor).
PrP Sc Tyr-Tyr-Arg reactivity is platform-independent
Using a 96-well sandwich ELISA system, we observed PrP Sc detection sensitivity with Tyr-Tyr-Arg monoclonal antibodies for capture, and a pan-PrP N-terminus polyclonal antibody for detection (Fig. 4a) . In these experiments, scrapie-to-normal ratios ranged up to 25-fold for the panel of monoclonal antibodies tested, using a 1,000-fold final dilution of mouse ME7 scrapie brain. These data suggest that TyrTyr-Arg antibodies may be useful in a robust high-throughput immunodetection system targeted against native PrP Sc .
Several important natural prion diseases (such as scrapie and variant CJD) are accompanied by agent accumulation in biopsy-accessi- ble peripheral lymphoid tissues. In mouse spleen, however, prion titers are at least 3-4 logs lower than those in brain 20, 21 , and PrP (27) (28) (29) (30) load in moribund animals is estimated to be at least 1-2 logs less than that of brain 21, 22 . Despite low levels of PrP Sc in spleen compared with brain (Fig. 4b, upper panel) , Tyr-Tyr-Arg monoclonal antibodies 17D10 and 1A12 immunoprecipitated PrP Sc from this tissue, but not PrP C (Fig. 4b, bottom panel) . These data indicate that the sensitivity of the Tyr-Tyr-Arg monoclonal antibodies is sufficient to maintain PrP isoform specificity even in the presence of high concentrations of heterologous proteins. In diseases accompanied by lymphoid replication of prions, PrP Sc preferentially accumulates in follicular dendritic cells (FDCs) [23] [24] [25] . Retropharyngeal lymph node dendritic cells (CD45RO -CD58 + ) from three of three scrapie-infected sheep displayed Tyr-Tyr-Arg surface immunoreactivity with the monoclonal antibody 9A4 (8-29% of cells), but not the 4E4 isotype-control monoclonal antibody (0-0.4%), whereas similar cells from three uninfected sheep did not stain with either monoclonal antibody (Fig. 4c) . No significant Tyr-Tyr-Arg surface immunoreactivity was observed on sheep or rodent lymphocytes, or on dissociated brain cells from end-stage ME7 scrapie-infected mice (data not shown), suggesting that FDCs may selectively accumulate cell-surface PrP Sc .
DISCUSSION
We believe that the Tyr-Tyr-Arg motif constitutes the first hypothesisdriven PrP Sc -selective epitope derived from consideration of isoformselective antibody accessibility to amino-acid side chains exposed during conformational conversion in prion diseases. Tyr-Tyr-Arg antibodies, in addition to recognizing the protease-resistant PrP that is key to most current diagnostic tests for prion infection, can also recognize misfolded but protease-sensitive PrP (Figs. 2d and 3c and data not shown). In prion disease, the latter, newly recognized molecular species 26 is characteristic of certain prion strains 27 , early prion infection [20] [21] [22] and interspecies prion transmission 28 . Protease-sensitive PrP Sc may represent a transient intermediate between normal structure and the abnormal, misfolded and aggregated PrP isoform that has acquired protease resistance 29 . The population of misfolded protease-sensitive molecules may also contain PrP*, the hypothetical PrP isoform responsible for the property of prion infectivity 30 .
We showed surface immunoreactivity for Tyr-Tyr-Arg on living dendritic cells from scrapie-infected sheep lymph nodes, suggesting that PrP Sc can be maintained in the native (infectious) conformation on these cells. FDCs are implicated in the immune presentation to B cells of native-structure antigens, complexed at the cell surface with antibody or complement or both 31 . Recent studies have shown a role for complement components 32, 33 and B cells 34 in lymphoid replication and subsequent neuroinvasion of prions. It is thus possible that native PrP Sc , perhaps complexed with complement, may accumulate on FDCs for immune presentation to other lymphoid cells, which become concurrently infected with prions. Immune presentation of PrP Sc must be ineffectual, as no antiprion humoral or cellular immune response has been detected in prion infection 35 .
The PrP Sc -selective Tyr-Tyr-Arg epitope may prove useful in immunotherapy or immunoprophylaxis of prion diseases. Recent findings show that antibodies directed predominantly against PrP C can clear scrapie-infected cells of PrP Sc in vitro 36, 37 and can block the propagation of experimental scrapie in transgenic mice in vivo 9 . However, autoimmune recognition of PrP C could cause inappropriate activation of signaling cascades 38 , immunosuppression 39 and widespread complement-dependent cellular lysis 40 , although in some experimental paradigms such antibodies are apparently tolerated 9, 41 . Considering the key role of dendritic cells in scrapie, BSE and variant CJD 23, 24, 25 , and the immunologic recognition of dendritic cell-surface PrP Sc by Tyr-Tyr-Arg antibodies in physiological buffers (Fig. 4c) , it is conceivable that circulating Tyr-Tyr-Arg antibodies could block prion neuroinvasion by neutralizing or opsonizing gut or lymphoid prions during the peripheral incubation phase of these diseases.
The isoform-selective exposure of Tyr-Tyr-Arg may help determine the structure of PrP Sc , for which only low-resolution fragmentary structures are currently available 42 . The three Tyr-Tyr-X motifs of PrP are apparently obscured to antibody recognition in PrP C by tertiary structural elements [14] [15] [16] and native post-translational modifications. We believe that the best candidate for the PrP Sc -selective epitope is the Tyr-Tyr-Arg motif located in the PrP C β-strand 2. In support of this idea, Tyr-Tyr-Arg monoclonal antibody binding is not inhibited by 6H4 antibody (recognizing an overlapping epitope in α-helix 1; ref. 7), Tyr-Tyr-Arg monoclonal antibody binding seems to be critically dependent on the terminal arginine residue (lacking in the Tyr-Tyr-Gln and Tyr-Tyr-Asp sequences of α-helix 3), and antibody access to the C terminus of native PrP (α-helix 3) does not differ for PrP C and PrP Sc (ref. 43) . Moreover, considering that access to all three side chains is necessary for Tyr-Tyr-Arg antibody binding, we speculate that β-strand 2 becomes exposed in disease as a result of the dissolution of the short β-sheet of PrP C . This notion is consistent with experimental data indicating that PrP Sc has features of a molten globule 12, 44 lacking some of the tertiary structural elements of PrP C .
The prion diseases may provide a prototype for disorders of protein misfolding, including Alzheimer disease, amyotrophic lateral sclerosis and Parkinson disease. We hypothesize that conformational conversion of proteins in disease is accompanied by molecular surface exposure of previously sequestered amino-acid side chains. It is possible that exploitation of this 'side-chain accessibility' hypothesis, applied here to isoform-selective antibodies for PrP, may provide new diagnostic and therapeutic approaches to other post-translational disorders of the proteome.
METHODS
Tyrosine and tryptophan fluorescence at varying pH. Recombinant mouse PrP(23-231) (400 nM; gift of K. Qin and D. Westaway, University of Toronto) dissolved in 1.5 M guanidine hydrochloride (Sigma), 2 mM sodium phosphate (Sigma) and 2 mM sodium citrate (Sigma) buffers was monitored by steady-state fluorescence using a 2 nm bandpass. The excitation and emission wavelengths were 275 nm and 310 nm for tyrosine fluorescence and 293 nm and 350 nm for tryptophan fluorescence measurements, respectively.
Acrylamide quenching of tyrosine fluorescence. PrP(23-231) (400 nM) in 1.5 M guanidine hydrochloride, 2 mM sodium phosphate and 2 mM sodium citrate was titrated with increasing concentrations of acrylamide (Sigma) at pH values of 7 and 3. Tyrosine fluorescence was measured using an excitation wavelength of 275 nm (bandpass of 2 nm) and an emission wavelength of 311 nm (bandpass of 7 nm). Stern-Volmer plots were obtained by plotting the ratio of the observed fluorescence in the absence of acrylamide to the fluorescence in the presence of acrylamide.
Antibody generation. Polyclonal antibody C2 was produced by immunizing rabbits with KLH-conjugated Cys-Tyr-Tyr-Arg peptide. IgG from sera were purified on a protein A-Sepharose column (Pharmacia Amersham). Monoclonal antibodies were developed by immunizing and thrice boosting mice with KLH-conjugated CYYRRYYRYY peptide, in Freund complete adjuvant. Initial screening was done by testing antibody reactivity on 4-MAPTyr-Tyr-Arg-coated plates. Positive IgM was purified by size fractionation from ascites fluid. Monoclonal antibody variable regions were cloned into a dog IgG framework from cDNA produced from hybridomas by PCR amplification. Light-and heavy-chain variable regions were amplified using forward primers specific to the leader sequences and reverse primers specific to the first exon of the constant regions. Dog light-and heavy-chain constant regions were amplified in a similar fashion. PCR products were annealed and amplified using primers specific to the outer ends. Overlapped light-and heavy-chain PCR fragments were cloned into pcDNA3 vectors. Plasmid DNA was transfected into 293 cells, at a 3:1 light-to-heavy chain molar ratio, using Lipofectamin2000 (Invitrogen) under standard conditions. Recombinant chimeric IgGs were purified on protein A-Sepharose. A polyclonal nondistinguishing antibody against PrP was produced by immunizing rabbits with a peptide corresponding to residues 23-56 of bovine PrP. IgG was purified from sera as described above.
Preparation of acidic guanidine-HCl-treated PrP. We mixed 100 µl of 10% brain homogenate with an equal volume of 3.0 M guanidine HCl (final concentration 1.5 M) in PBS at pH 7.4 or pH 3.5 adjusted with 1 N HCl, followed by incubation at room temperature with shaking. After 5 h, samples were mixed with five volumes of prechilled methanol and incubated at -20 °C for 2 h to precipitate the proteins. The samples were subjected to centrifugation at 16,000 g for 20 min at 4 °C to remove the acidic buffer and guanidine HCl, and pellets were resuspended in 100 µl of lysis buffer. The samples treated at pH 7.4 were designated as mock-treated samples.
Peptide ELISA. Hybridoma supernatants were produced by culturing hybridoma cells in DMEM (Wisent) supplemented with 20% FBS (Wisent). The culture medium was separated from the cells by centrifugation (1,000 g) for 10 min. Supernatants were diluted one-third in medium with 10% FCS and incubated with the indicated 4-MAP-peptide conjugates at 1 mg/ml final concentration for 2 h at 20-24 ο C. Immulon-4 96-well plates (Dynex) were coated with 100 µl of peptide diluted to 10 µg/ml in 100 mM carbonate buffer (pH 9.6). The coated plates were blocked with PBS and 1% BSA (Sigma) for 2 h at room temperature. The supernatant mixtures were added to the 4-MAP-Tyr-Tyr-Arg-coated plates for 30 min. After 6-8 washes with PBS and 0.5% Tween 20, bound antibody was revealed using a horseradish peroxidase-labeled goat antibody to mouse immunoglobulin, diluted 1:3,000.
Bead ELISA. Five microliters of mouse 10% brain homogenates were incubated with 15 µl of magnetic bead-conjugated antibodies to Tyr-Tyr-Arg in 0.2 ml of immunoprecipitation binding buffer for 2 h at 20-24 ο C with shaking. Washes were done in a similar fashion to the usual immunoprecipitation. Captured PrP Sc was detected with purified rabbit IgG to PrP, followed by horseradish peroxidase-labeled donkey antibody to rabbit immunoglobulin (Jackson), diluted 1:1,000.
Flow cytometry. Fresh retropharyngeal lymph nodes from normal and scrapie-infected sheep were processed as modified from ref. 45 . The tissue was dissected into small chunks and incubated three times, at 37 ο C for 15 min, with a solution containing 0.15 mg/ml Blenzyme I (Roche Diagnostics) and 0.03 mg/ml DNase I (Roche Diagnostics). Viable lymph node cells were sequentially incubated for 15 min on ice with normal mouse serum, antibody to sheep CD58 (VMRD, Inc.), phycoerythrin-conjugated goat antibody to mouse IgG1 (Southern Biotech Associates), antibody to sheep CD45RO (VMRD, Inc.), biotin-conjugated goat antibody to mouse IgG3 (Southern Biotech Associates), phycoerythrin-Cy5-conjugated streptavidin (Serotec) and 10 µg/ml of either a PrP Sc -specific antibody or the isotype control, followed by FITC-conjugated goat antibody to mouse IgM (Southern Biotech Associates). All antibody dilutions and washes were done using Dulbecco PBS supplemented with 2.5% FBS.
Note: Supplementary information is available on the Nature Medicine website.
